Pipeline

Aducanumab is a human monoclonal antibody against beta amyloid in development for the treatment of Alzheimer's disease. In 2024, Neurimmune regained global rights to aducanumab from Biogen and aims to develop aducanumab-based therapeutics that can be subcutaneously administered.

*The U.S. FDA granted accelerated approval for intravenously administered aducanumab-avwa for the treatment of Alzheimer’s disease.

NI006, is a human antibody that exclusively targets with high affinity the disease-associated amyloid conformation but not physiological forms of transthyretin. NI006 targets both wild-type ATTR as well as ATTR mutants that are linked to hereditary forms of ATTR cardiomyopathy and ATTR polyneuropathy. NI006 induces the clearance of pathological ATTR in preclinical models. Currently, NI006 is in Phase 3 clinical development in ATTR cardiomyopathy patients (NCT06183931).

In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006. >>Link to announcement

AP-101 is a human antibody directed against misfolded superoxide dismutase 1 (SOD1). Currently, safety, tolerability, pharmacokinetics and pharmacodynamics of AP-101 are assessed in patients with ALS. Neurimmune and TVM Capital Life Science created AL-S Pharma AG to develop AP-101 to human proof-of-concept. AL-S Pharma engages with Chorus, an autonomous unit of Eli Lilly and Company, to execute on an innovative clinical plan in collaboration with an international network of ALS experts.

NI004 is a small chemical analog of the cholinergic neurotransmitter acetylcholine in development for the treatment of patients with cholinergic deficits. In addition to Alzheimer’s disease, patients with Lewy body dementia or Parkinson’s disease dementia suffer from such cholinergic deficits.

NI008 is a human antibody specifically targeting pathological protein produced by a mutant C9orf72 gene. The antibody showed in preclinical models to lower neuroinflammation, slow neurodegeneration and lengthen survival in the most common genetic form of amyotrophic lateral sclerosis, or ALS, and frontotemporal dementia, or FTD.

NG004 is a human antibody blocking the function of Nogo-A, one of the most potent and well-studied nerve growth inhibitors. NG004 is developed by NovaGo Therapeutics for the treatment of spinal cord injury. Novago Therapeutics is a spin-off company from the University of Zurich that entered into a strategic partnership with Neurimmune to discover human antibodies targeting Nogo-A. NovaGo Therapeutics was founded by Prof. Martin Schwab based on the discovery of the existence of “inhibitors of nerve fiber growth” as a cause of the absence of regeneration of injured fiber tracts in the central nervous system.

NI203 is a human antibody that targets pathologic IAPP aggregates and neutralizes their toxicity. In preclinical models of type-2 diabetes NI203 supported normal beta cell functions resulting in re-stored insulin secretion and reduction of the type-2 diabetes symptoms.